Skip to content

The Effects of Two Different Treatment Protocols on Shoulder Function, Quality of Life, and Ultrasound Parameters in Patients With Frozen Shoulder

The Effects of Two Different Treatment Protocols on Shoulder Function, Quality of Life, and Ultrasound Parameters in Patients With Frozen Shoulder

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05956171
Enrollment
50
Registered
2023-07-21
Start date
2023-10-01
Completion date
2024-03-31
Last updated
2023-10-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Frozen Shoulder, Shoulder Capsulitis, Shoulder Pain

Keywords

hydrodilatation, hydrodistension, ultrasound

Brief summary

The goal of this interventional study is to compare the outcomes of two different injection aprroaches in patients with frozen shoulder. The main questions it aims to answer are: * Is hydrodilatation better than intraarticular corticosteroid injection? * Is there any prognostic factors that will help clinicians guide their decision making when choosing between these two treatments? Participans will receive an injection(cortcosteroid and local anesthetics alone or with hydrodilatation-corticosteroid and local anesthetics plus sterile saline solution) and then they will follow a rehabilitation program.

Interventions

5 ml blind intra-articular corticosteroid injection

OTHERUltrasound Guided Hydrodilatation with corticosteroid injection

15 ml intra-articular injection to shoulder via anterior approach under ultrasound guidance

Sponsors

Istanbul University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Intervention model description

Two-arm study with one hydrodilatation group compared with the standart treatment group(cortisteroid injection)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients who fulfill the diagnostic criteria for frozen shoulder * Agree to participate in the study * Having the opportunity to follow up for at least 3 months

Exclusion criteria

* Refusing to participate in the study * History of shoulder injection in the last 3 months * Having diabetes mellitus * Presence of comorbidities that contraindicate injection therapy, such as bleeding diathesis * Known history of allergy or anaphylaxis to drugs used in treatment

Design outcomes

Primary

MeasureTime frameDescription
Change from baseline pain score on Visual Analog Scale(VAS)Baseline, 1 week, 1 month, 3 monthsPain scored according to VAS; between 0(no pain) to 10(worst pain)
Change in Shoulder Pain and Disability Index(SPADI) scoresBaseline, 1 month, 3 monthsScored between 0-10 ; 0 means no pain and disability and 10 means the worst pain and disability

Secondary

MeasureTime frameDescription
Proprioception(Active position sense- joint position error)Baseline, 3 monthsShoulder joint is positioned in 30 degree flexion and 15 degree internal and external rotation in lying position, patient is asked to position their joints and errors in degrees noted
Shoulder StrengthBaseline, 3 monthsMeasured with cybex isokinetic dinamometer, shoulder flexion/extension and shoulder internal/external rotation
Change in Range of Movement(ROM)Baseline, 1 week, 1 month, 3 monthsRange of shoulder movements assessed with digital inclinometer in sittting and lying positions
Changes in Life Quality ScoreBaseline, 1 month, 3 monthsItems from the SF-36 (Short Form 36) survey, between 0(worst) to 100(best)
Treatment Satisfaction3 monthsGlobal Improvement and Satisfaction Score, between 1 to 5, 1 very dissatisfied, and 5 very satisfied
Changes in Depression ScoreBaseline, 1 months, 3 monthsmeasured by Beck's Depression Inventory(between 0 to 40), 0 means no depression and 40 means severe depression
Ultrasound ParametersBaseline, 1 month, 3 monthsCoracohumeral ligament(CHL) thickness, axillary pouch(AP) thickness, elastography of deltoid muscle(anterior, middle, and posterior)

Contacts

Primary ContactFatmanur Yegin
fatmanur.yegin@istanbul.edu.tr0905462729955

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026